Announcements Trials
Browse Landscape

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 17INDUSTRY 5NIH 3NETWORK 3OTHER_GOV 1

Study Type

Observational 5

Sponsor

Cancer Type

Thoracic 8Breast 6Genitourinary 5Gastrointestinal 5Other hematologic neoplasm 3Lymphoid 2Gynecologic 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Head & Neck 1CNS 1

Conditions

Prostatic Neoplasms 5Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia 1Laryngeal Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Bone Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Observation × Genitourinary × Clear all
NCT05323747 2025-09-16

BP-008

BioProtect

Completed
20 enrolled
Genitourinary

Prostatic Neoplasms

NCT05354427 2025-09-16

CLP-10095

BioProtect

Completed
175 enrolled
Genitourinary

Prostatic Neoplasms

NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT05423431 2022-06-24

Retrospective Evaluation of a Commercially Available Hydrogel Spacer (BP-009)

BioProtect

Completed
19 enrolled
Genitourinary

Prostatic Neoplasms

NCT00754000 2012-04-30

AIM

Varian, a Siemens Healthineers Company

Completed
82 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡